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INTRODUCTION 
Naproxen sodium (NAP) is chemically, (S)-6-methoxy-α-
methyl-2-naphthaleneacetic acid, sodium salt (Fig.1A). 
NAP is a non-steroidal anti-inflammatory drug (NSAID) 
commonly used for the reduction of moderate to severe 
pain, fever, inflammation and stiffness. It works by 
inhibiting both the COX-1 and COX-2 enzymes. Like 
other NSAIDs, naproxen is capable of producing 
disturbances in the gastrointestinal tract. Several 
chromatographic methods have been reported for 
determination of NS in raw material1, tablets2-4, plasma5-7, 
urine8, intestinal perfusion samples 9 and pharmaceutical 
preparations 10-11.  Sumatriptan succinate (SUMA) is 
chemically, 3-[2-(dimethylamino)ethyl]-N-methyl-indole-
5- methanesulfonamide succinate (1:1) (Fig.1B). SUMA is 
a selective 5-hydroxytryptne1 receptor subtype agonist. 
Sumatriptan succinate is official in European 
Pharmacopoeia 12 and United States Pharmacopoeia 13, 
where chromatographic methods for sumatriptan succinate 
in bulk and tablet formulation were reported. Several 
analytical techniques like HPLC 14-15 and LS-MS 16-19 have 
been reported for sumatriptan succinate in combination 
with other drugs. 
In recent years pharmaceutical preparations containing 
both these drugs have been available commercially. 
Although, many methods for estimation of NAP and 
SUMA individually have been reported in the literature, 
very few methods are available for their simultaneous 
determination, hence we have developed a simple HPLC 
spectrophotometric method for the simultaneous 
determination of NAP and SUMA in tablet dosage form.  
EXPERIMENTAL 
Reagents: 
Gift samples of SUMA and NAP were procured from Sun 
Pharmaceutical Ltd., Vadodara, Gujarat. Commercially 
available Treximet tablets (containing 85 mg SUMA and 
500 mg NAP) were obtained from GlaxoSmithKline. All 
other chemicals and solvents used were of HPLC grade. 
 
Equipments and apparatus: 
A Shimadzu HPLC, CP224S analytical balance (Sartorius) 
and ultra sonic cleaner (Frontline FS 4) were used, 
Injector(Rheodyne,20μl), Sonicator, pH meter, Vaccum 
filter pump, Millipore filtration kit, mobile phase reservoir, 
Water bath, Sample filtration assembly and glassware’s 
were used throughout the experiment. 
Chromatographic conditions: 
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Analysis was carried at 229nm using a C 18 column 
(Phenomenex-Gemini 250mm x 4.6mm, 5 μm) at ambient 
temperature. The mobile phase consisted of Acetonitrile: 
Methanol: phosphate buffer pH 6 (50:10:40 v/v)  was set at 
a flow rate of1.0ml/min. 
Preparation of Mobile phase: 
To 500 ml of Acetonitrile, add 100 ml of methanol and 
400 ml of phosphate buffer pH 6 were added.  Then the 
mobile phase was degassed by sonicating for 20min. 
Diluent Preparation: 
Use the mobile phase as diluent. 
Standard Stock Solution (S1): 
Accurately weighed 2.5 mg of Sumatriptan Succinate 
Working Reference Standard (WRS) was transferred into a 
25ml volumetric flask. In the same flask accurately 
weighed 2.5 mg of Naproxen sodium was added.  
Then 15ml of mobile phase was added and mixed to 
dissolve.  
Then it was diluted up to 25 ml. (100 μg/ml of Sumatriptan 
Succinate and 100 μg/ml solution of Naproxen sodium)  
Preparation of sample solution: 
10 tablets (Treximet )were weighed and found to be 
7.45gms. Tablet powder weight equivalent to 4 mg of 
Sumatriptan Succinate and 25 mg Naproxen sodium was 
weighed and transferred into 50 ml volumetric flask. The 
powder was first dissolved with a 20ml of mobile phase 
and sonicated for 15 minutes. Then filtered through 
Whattman filter paper, the filtrate was collected and the 
volume was made up to 50 ml with the mobile phase. 
From this 1 ml of the solution was taken and made up to 
100 ml with mobile phase to get concentration of 5 mcg/ml 
naproxen sodium and 0.8 mcg/ml 
METHOD VALIDATION 
The chromatographic conditions were validated by 
evaluating specificity, linearity, accuracy, method and 
system precision, limit of detection (LOD), limit of 
quantification (LOQ), ruggedness, and robustness in 
accordance with ICH guideline Q2(R1) 
Linearity 
Standard stock solution was further diluted to obtain 1 
μg/mL, 2 μg/mL, 3 μg/mL, 4 μg/mL, 5 μg/mL, 6 μg/mL of 
Sumatriptan Succinate and Naproxen sodium in 
combination Twenty microlitre of the each standard 
solution was injected and chromatograms were recorded. 
Method and system precision 
Precision of the method was verified by repeatability 
(system precision) and intermediate precision (method 
precision) studies. Repeatability studies were performed by 
six replicate injections of 2 μg/ml of Sumatriptan 
Succinate and 2 μg/ml solution of Naproxen sodium on the 
same day. The studies were replicated on different days to 
determine intermediate precision. 
Accuracy 
Accuracy of the method was carried out by applying the 
method to drug sample to which known amount of DOM 
and NAP standard powder corresponding to 50%, 100% 
and 150% of label claim had been added (standard addition 
method), the solutions are analyzed by optimized method. 
Limit of detection (LOD) and Limit of quantification 
(LOQ) 
The limit of detection (LOD) is the lowest amount of 
analyte in a sample that can be detected, but not 
necessarily quantified, under the stated experimental 
conditions. LOD & LOQ was calculated by using standard 
deviation and slope values obtained from calibration curve. 
LOD = 3.3 σ/ S 
LOQ = 10 σ/ S 
Where, σ is standard deviation (intercept of calibration 
line);  
S is slope. 
Robustness of the method 
To evaluate robustness of the HPLC method, Slight 
variations were made in pH of Mobile phase was changed 
6  to  5.8 and 6.2.Slight variations were made amount of 
organic phase in mobile phase 
RESULTS AND DISCUSSIONS 
In the proposed work a HPLC method was developed and 
validated successfully for simultaneous estimation of 
Sumatriptan succinate and naproxen sodium. The method 
utilizes a Reverse Phase C18 column (Phenomenex-
Gemini 250mm x 4.6mm, 5 µm) with mobile phase of 
Acetonitrile: Methanol: Phosphate buffer in the ratio of 
50:10:40 at pH 6 at the flow rate of 1 ml/min and UV 
detection at 229nm for Sumatriptan succinate and 
naproxen sodium. 
The developed method was then validated by using various 
validation parameters like System suitability, Specificity, 
Limit of Detection, Limit of Quantification, Linearity, 
Precision, Accuracy and Robustness as per ICH guidelines. 
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Figure 3: the retention times of Sumatriptan succinate and naproxen sodium were 2.800 and 4.027 min, respectively 
In the proposed work a HPLC method was developed and 
validated successfully for simultaneous estimation of 
Sumatriptan succinate and naproxen sodium. The method 
utilizes a Reverse Phase C18 column (Phenomenex-
Gemini 250mm x 4.6mm, 5 µm) with mobile phase of 
Acetonitrile: Methanol: Phosphate buffer in the ratio of 
50:10:40 at pH 6 at the flow rate of 1 ml/min and UV 
detection at 229nm for Sumatriptan succinate and 
naproxen sodium. 
The developed method was then validated by using various 
validation parameters like System suitability, Specificity, 
Limit of Detection, Limit of Quantification, Linearity, 
Precision, Accuracy and Robustness as per ICH guidelines.  
Specificity of the method was determined and there was 
no visible peak in the retention time up to duration of 15 
min indicating that the diluent, excipients used in tablet 
formulation, impurities degradation products and matrix 
components do not interfere with the peak of Sumatriptan 
succinate and naproxen sodium, indicating a high degree 
of specificity for the proposed method. 
Linearity of the drugs response was found to be in the 
concentration  range of Sumatriptan succinate and 
naproxen sodium 1 to 5 µg/ml as the percentage curve 
fitting for  Sumatritan succinate was found to be 99.4 % 
(correlation coefficient:0.994) and for 99.99% (correlation 
coefficient: 0.999) for Naproxen sodium. 
The Limit of detection was determined and it was found to 
be 0.17(µg/mL) and 0.18 (µg/mL) for Sumatriptan 
succinate and naproxen sodium which indicates that even 
the small concentrations of the samples can be determined. 
The limit of quantification was found to be 0.53 (µg/mL) 
and 0.53 (µg/mL) for Sumatriptan succinate and naproxen 
sodium respectively which indicates that the concentration 
in micrograms level can be quantified with acceptable 
accuracy and precision. 
Precision of the system and method was determined by 
replicate injection of standard and sample solution. The 
%RSD of peak area for Sumatriptan succinate and 
naproxen sodium was found to be 0.850% and 0.881% 
respectively which was well within the acceptance criteria 
for system precision. 
 
Table 2: precision data for Sumatriptan succinate and naproxen sodium 
Sr no. Sumatriptan succinate Naproxen sodium  
RT Peak Area RT Peak Area 
1 2.776 324.598 4.056 292.953 
2 2.816 326.216 4.121 294.456 
3 2.824 324.156 3.997 296.341 
4 2.849 320.681 4.114 291.334 
5 2.794 322.745 4.106 289.583 
6 2.785 328.657 4.074 295.543 
Average 2.807 324.509 4.078 293.368 
S.D. 0.027 2.757 0.047 2.584 
% R.S.D. 0.975 0.850 1.150 0.881 
 
The percentage relative standard deviations (%RSD) of 
assay for method precision at three different 
concentration (3 µg/ml, 4 µg/ml, 5 µg/ml) was found to  be  
1.29, 1.42 and 1.71 respectively for Sumatriptan succinate 
and 1.31, 0.80, 0.91 respectively for  Naproxen sodium, 
which was well within limit of not more than 2.0%. Hence 
the proposed method was found to provide high degree of 
precision and reproducibility (Table 1) 
The intermediate precision of the method was determined 
by carrying out the assay by different analyst and by 
performing the assay on different days to check the 
reproducibility. The test result were found to be 
satisfactory with relative standard deviation (%RSD) for 
set of analysis on the same day and different days being 
less than 2.0 % for both Sumatriptan succinate and 
naproxen sodium and hence the proposed HPLC method is 
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found to be Rugged.   
Accuracy was determined through recovery studies of the 
Sumatriptan succinate and naproxen sodium at three 
different levels 50%, 100% and 150%. Sumatriptan 
succinate and naproxen sodium showed recovery of 99.87 
to 101.08% and 100.11 to 100.80 %( Table 2) which were 
found to  be  well  within the  acceptance  limit  of  98-102 
%, indicating practically no interference of the drugs with 
each other or with the excipients present in the formulation 
for the proposed method indicating that the HPLC  method 
developed  for estimation of Sumatriptan succinate and 
naproxen sodium simultaneously is accurate.
 
Table 2: Accuracy data for Sumatriptan succinate and naproxen sodium 
S No. %concentration of spiked level Sumatriptan succinate  Naproxen sodium  
1 80% 100.11 100.11 
2 100% 101.08 100.42 
3 120% 99.87 100.80 
 
Robustness of the HPLC method developed was 
determined by deliberately changing mobile phase ratio 
and pH of the mobile phase slightly. The percentage 
%RSD of peak area, tailing factor, theoretical plates and 
resolution were found to be well within the acceptance 
criteria indicating that the proposed method is robust.  
The HPLC method developed and validated for 
simultaneous estimation of Sumatriptan succinate and 
naproxen sodium was found to be linear, accurate, precise, 
stable, rugged and robust. 
The proposed method was then applied for determination 
of Sumatriptan succinate and naproxen sodium in the 
formulation TREXIMET Tablet.  The  percentage  purity  
of  Sumatriptan succinate and naproxen sodium in tablets  
was  found to  be  in the  range  of  98.93%  to  99.62%  
and 99.89%  to  101.18% respectively which was found 
well within the acceptance limit of 95 to 105% (Tablet 
No.III). Hence the HPLC method developed and validated 
can be routinely used for simultaneous determination of 
Sumatriptan succinate and naproxen sodium in 
formulations (tablets). 
  
Table 3: Assay of Sumatriptan succinate and naproxen sodium by RP-HPLC DRUG Sample 
Sumatriptan succinate Naproxen sodium  
Conc. Peak area Conc. (µg/ml) % Assay Conc. Peak area Conc. (µg/ml) % Assay 
0.8 71.98 23.74 98.93 5 1041.18 151.78 101.18 
0.8 72.16 23.80 99.18 5 1038.27 151.35 100.90 
0.8 72.48 23.91 99.62 5 1027.88 149.84 99.89 
Average 99.24 Average 100.66 
 
These developed methods provide selective quantification 
of drug without any interference from blank and placebo 
and are highly sensitive, reproducible, reliable, rapid and 
specific. Analysis by these methods were found to be 
simple, accurate, reproducible, precise, and in good 
agreement with labeled claim of the drug. 
Statistical evaluation was carried out on all the developed 
methods and no significant difference was achieved 
between the methods. Thus the developed methods can be 
easily used for the drug analysis in routine quality control 
CONCLUSION 
The proposed method was found to be simple, precise, 
accurate and rapid for simultaneous determination of 
Sumatriptan succinate and Naproxen sodium. The mobile 
phase is simple to prepare and economical. The sample 
recoveries in all formulations were in good agreement with 
their respective label claims and they suggested 
noninterference of formulation excipients in the 
estimation. Hence, the method can be easily and 
conveniently adopted for routine analysis of Sumatriptan 
succinate and Naproxen sodium. 
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